Farletuzumab Ecteribulin provides a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) for cancer and oncology research. Also known as MORAb-202, it combines an FRα-directed monoclonal antibody with an eribulin-derived cytotoxic payload and specifically supports studies of targeted cytotoxicity, ovarian cancer, and antibody-mediated drug delivery.
Key Features and Benefits
- FRα-Targeting ADC: Combines a folate receptor alpha-directed monoclonal antibody with an eribulin-derived cytotoxic payload.
- Eribulin Payload: Contains a microtubule dynamics inhibitor that specifically supports investigation of ADC-mediated cytotoxicity.
- Folate Receptor Alpha Recognition: Supports studies of FRα expression, antibody binding, internalization, and tumor-targeting mechanisms.
- Cleavable Linker: Uses a protease-cleavable linker designed to facilitate intracellular payload release following cellular uptake.
- Targeted Payload Delivery: Supports investigation of antibody-mediated delivery of eribulin-derived payloads to FRα-expressing cancer cells.
- Microtubule Inhibition: The eribulin-derived payload disrupts microtubule dynamics, specifically supporting studies of cell-cycle arrest and cytotoxic responses.
- MORAb-202 Research Platform: Provides an investigational ADC platform specifically for studying FRα-directed cancer targeting and payload activity.
Applications
- Ovarian Cancer Research: Supports investigation of FRα-targeted ADC mechanisms in ovarian cancer models.
- FRα-Positive Cancer Research: Useful for studying tumors with elevated folate receptor alpha expression.
- Endometrial Cancer Research: Supports evaluation of FRα-directed ADC strategies in relevant endometrial cancer models.
- Solid Tumor Research: Especially useful for investigating FRα-targeted cytotoxicity across compatible solid tumor models.
- ADC Research: Supports studies of antibody targeting, internalization, payload release, and cytotoxic activity.
- Targeted Cancer Research: Useful for investigating antibody-mediated delivery of eribulin-derived cytotoxic payloads.
- Cell-Based Cancer Assays: Supports evaluation of FRα-dependent binding, cellular uptake, and cytotoxic responses.
- Mechanism-of-Action Studies: Supports investigation of FRα targeting and eribulin-mediated microtubule inhibition.
Storage and Handling
- Storage: Store according to the product specification under recommended temperature conditions. Protect from excessive heat and repeated freeze-thaw cycles.
- Handling: Handle using appropriate procedures for antibody-drug conjugates and cytotoxic research materials. Maintain conditions that preserve antibody and conjugate stability.
Farletuzumab Ecteribulin combines FRα-directed antibody targeting with an eribulin-derived microtubule inhibitor payload and specifically supports ovarian cancer, FRα-positive solid tumor, ADC, and targeted drug delivery research.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
